International trade · 14/06/2001Updated: 10/17/2026 · 1 min read
U.S. International Trade Commission Waives Rights in Changzhou Huabang Pharmaceutical Group Investigation
Summary
The U.S. International Trade Commission has decided not to review an initial determination finding Changzhou Huabang Pharmaceutical Group, Ltd. in default, and has waived its rights to participate in the investigation.
Original source language: Federal Register — International Trade CommissionOpen original release →